Luminex Corporation (NASDAQ:LMNX) Director Robert J. Cresci sold 19,631 shares of the stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $18.98, for a total transaction of $372,596.38. Following the sale, the director now directly owns 260,358 shares in the company, valued at $4,941,594.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Luminex Corporation (LMNX) traded up 0.11% during mid-day trading on Friday, hitting $18.89. 96,433 shares of the company were exchanged. The stock’s 50 day moving average is $20.09 and its 200-day moving average is $19.59. Luminex Corporation has a 12-month low of $17.64 and a 12-month high of $23.62. The company has a market cap of $832.50 million, a price-to-earnings ratio of 58.48 and a beta of 0.29.
Luminex Corporation (NASDAQ:LMNX) last released its quarterly earnings data on Monday, August 7th. The medical instruments supplier reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.11. The business had revenue of $76.50 million for the quarter, compared to analyst estimates of $75.45 million. Luminex Corporation had a return on equity of 4.81% and a net margin of 4.72%. Luminex Corporation’s revenue was up 19.2% compared to the same quarter last year. During the same period last year, the firm posted $0.33 earnings per share. Equities research analysts predict that Luminex Corporation will post $0.51 EPS for the current year.
WARNING: “Luminex Corporation (LMNX) Director Robert J. Cresci Sells 19,631 Shares” was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://stocknewstimes.com/2017/08/25/luminex-corporation-lmnx-director-robert-j-cresci-sells-19631-shares.html.
A number of analysts have weighed in on the stock. TheStreet cut shares of Luminex Corporation from a “b” rating to a “c+” rating in a report on Monday, August 7th. BidaskClub cut shares of Luminex Corporation from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 9th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $21.00 price objective on shares of Luminex Corporation in a report on Friday, June 9th. Zacks Investment Research raised shares of Luminex Corporation from a “hold” rating to a “strong-buy” rating and set a $22.00 price objective on the stock in a report on Thursday. Finally, ValuEngine raised shares of Luminex Corporation from a “sell” rating to a “hold” rating in a report on Thursday, May 11th. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $21.40.
A number of hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE raised its stake in Luminex Corporation by 9.9% in the first quarter. Bank of America Corp DE now owns 322,154 shares of the medical instruments supplier’s stock valued at $5,917,000 after buying an additional 29,107 shares during the period. BlackRock Inc. raised its stake in Luminex Corporation by 52,547.0% in the first quarter. BlackRock Inc. now owns 5,063,064 shares of the medical instruments supplier’s stock valued at $93,008,000 after buying an additional 5,053,447 shares during the period. Creative Planning raised its stake in Luminex Corporation by 5.4% in the first quarter. Creative Planning now owns 9,256 shares of the medical instruments supplier’s stock valued at $170,000 after buying an additional 474 shares during the period. Karp Capital Management Corp acquired a new stake in Luminex Corporation during the first quarter valued at $225,000. Finally, Nationwide Fund Advisors raised its stake in Luminex Corporation by 58.8% in the first quarter. Nationwide Fund Advisors now owns 48,593 shares of the medical instruments supplier’s stock valued at $893,000 after buying an additional 17,996 shares during the period. 73.36% of the stock is currently owned by institutional investors and hedge funds.
About Luminex Corporation
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.
Receive News & Ratings for Luminex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
